#1 Clinical Trials Search in Europe

Gen1055

GEN1055, also known as HexaBody-OX40, is an investigational drug currently being studied in clinical trials for patients with malignant solid tumors. This article will provide an overview of the ongoing research, including the drug’s potential benefits, safety profile, and its use both as a standalone treatment and in combination with other therapies.

Table of Contents

What is GEN1055?

GEN1055, also known as HexaBody-OX40 or BNT315, is a new drug being developed to treat various types of malignant solid tumors[1]. Malignant solid tumors are cancerous growths that form in organs or tissues of the body. This medication is currently in the early stages of clinical trials, which means it’s being tested to see how safe and effective it is for treating cancer patients.

How does GEN1055 work?

GEN1055 is a type of drug called a monoclonal antibody. These are laboratory-made proteins that act like human antibodies in the immune system. GEN1055 is designed to target a specific protein called OX40, which is found on certain immune cells. By interacting with OX40, GEN1055 aims to boost the body’s immune response against cancer cells[1].

What conditions does GEN1055 treat?

GEN1055 is being studied for the treatment of various types of malignant solid tumors. These can include cancers of different organs such as the lung, breast, colon, or other parts of the body. The current clinical trial is focusing on patients whose cancer has spread or become advanced, and who have already tried other standard treatments without success[1].

Current research on GEN1055

A clinical trial is currently underway to study GEN1055. This trial has two main parts[1]:

  1. Dose Escalation Phase (Phase 1a and 1b): This part of the study aims to:
    • Evaluate the safety of GEN1055 when used alone and when combined with another cancer drug called pembrolizumab
    • Determine the best doses of GEN1055 for future studies
    • Look at how the body processes GEN1055 (known as pharmacokinetics or PK)
    • Check if the body develops antibodies against GEN1055 (immunogenicity)
    • See if there are any early signs that the treatment is working against the cancer
  2. Expansion Phase: This part of the study will:
    • Further assess how well GEN1055 works against cancer, both alone and in combination with pembrolizumab
    • Continue to evaluate the safety and how the body processes the drug

Potential benefits of GEN1055

While it’s too early to know for sure how effective GEN1055 will be, researchers hope it may offer several potential benefits[1]:

  • It may help fight cancer in patients who have not responded well to other treatments
  • It might work even better when combined with other cancer drugs like pembrolizumab
  • By targeting the immune system, it may offer a different approach to treating cancer compared to traditional chemotherapy

Safety and side effects

As GEN1055 is still in early clinical trials, all of its potential side effects are not yet known. The current study is closely monitoring for any adverse events (side effects). Some things to note[1]:

  • The study is carefully tracking any side effects that occur
  • Patients with certain pre-existing conditions, such as active infections, significant heart problems, or autoimmune diseases, may not be eligible for the trial due to potential risks
  • The researchers are particularly watchful for immune-related side effects, as GEN1055 works by affecting the immune system

Who can participate in GEN1055 trials?

The current clinical trial has specific criteria for who can participate. Some key points include[1]:

  • Participants must be at least 18 years old
  • They must have a type of cancer that is considered a malignant solid tumor
  • Their cancer must be advanced or have spread, and previous standard treatments must not have worked
  • They need to be in relatively good overall health, with adequate organ function
  • Some medical conditions or previous treatments may disqualify a person from participating

It’s important to note that participating in a clinical trial is a decision that should be made carefully, in consultation with your healthcare provider. While trials offer access to new treatments, they also come with risks and uncertainties.

Aspect Details
Drug Name GEN1055 (HexaBody-OX40)
Trial Phase Phase 1/2a
Target Condition Malignant Solid Tumors
Treatment Approaches Monotherapy and Combination with Pembrolizumab
Primary Objectives Safety evaluation, Dose determination, Antitumor activity assessment
Key Eligibility Criteria Adults with advanced/metastatic solid tumors, Measurable disease, Adequate organ function
Main Exclusion Criteria Uncontrolled illnesses, Active infections, Significant autoimmune diseases
Primary Endpoints Adverse events, Dose-limiting toxicities, Overall response rate
Secondary Endpoints Pharmacokinetics, Immunogenicity, Duration of response, Progression-free survival, Overall survival

FAQ

  • What is GEN1055 and what is it being studied for? GEN1055, also known as HexaBody-OX40, is an investigational drug being studied for the treatment of malignant solid tumors. It is being tested both as a standalone therapy and in combination with another drug called pembrolizumab.
  • What is the main goal of the clinical trial for GEN1055? The main goal of the clinical trial is to evaluate the safety of GEN1055 when used alone and in combination with pembrolizumab. The trial also aims to determine the appropriate doses for future studies and assess the drug's potential anti-tumor activity.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with advanced or metastatic solid tumors who have progressed on standard therapies. They must have measurable disease and meet specific health criteria, including adequate organ function and performance status.
  • What are some of the exclusion criteria for the trial? Some exclusion criteria include uncontrolled illnesses, active infections, significant autoimmune diseases, history of severe immune-related side effects from previous cancer treatments, and certain liver conditions. Recent cancer treatments or radiation therapy may also exclude participation.
  • How is the effectiveness of GEN1055 being measured in this trial? The effectiveness of GEN1055 is primarily measured by the overall response rate (ORR) of tumors according to standard criteria (RECIST v1.1). Other measures include the duration of response, time to response, and disease control rate. The trial also assesses progression-free survival and overall survival in expansion cohorts.

Ongoing Clinical Trials on Gen1055

  • Study on the Safety and Effects of GEN1055 Alone and with Pembrolizumab for Patients with Malignant Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • GEN1055: An investigational drug also known as HexaBody-OX40, being studied for the treatment of malignant solid tumors.
  • Malignant Solid Tumors: Cancerous growths that form masses of tissue, excluding blood cancers. These tumors can occur in various parts of the body.
  • Pembrolizumab: An immunotherapy drug used in combination with GEN1055 in some parts of the clinical trial.
  • Monotherapy: Treatment using a single drug, in this case, GEN1055 alone.
  • Combination Therapy: Treatment using multiple drugs together, such as GEN1055 with pembrolizumab.
  • Dose Escalation: A process in clinical trials where the dose of a drug is gradually increased to find the optimal safe and effective dose.
  • ECOG PS: Eastern Cooperative Oncology Group Performance Status, a scale used to assess how a patient's disease affects their daily living abilities.
  • RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure if tumors are responding to treatment.
  • ORR: Overall Response Rate, the proportion of patients whose cancer shrinks or disappears after treatment.
  • PFS: Progression-Free Survival, the length of time during and after treatment that a patient lives without the cancer progressing.
  • OS: Overall Survival, the length of time from the start of treatment that patients are still alive.
  • AEs: Adverse Events, any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • DLTs: Dose-Limiting Toxicities, side effects severe enough to prevent an increase in dose or level of treatment.
  • PK: Pharmacokinetics, the study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • ADA: Anti-Drug Antibodies, antibodies that the body produces against a therapeutic drug, which can affect its efficacy and safety.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-gen1055-alone-and-with-pembrolizumab-for-patients-with-malignant-solid-tumors/